ST. HELIER, Jersey (AP) — ST. HELIER, Jersey (AP) — NovoCure Ltd. (NVCR) on Thursday reported a loss of $24.5 million in its fourth quarter.
The St. Helier, Jersey-based company said it had a loss of 22 cents per share.
The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 41 cents per share.
The oncology drug developer posted revenue of $174.4 million in the period, also surpassing Street forecasts. Four analysts surveyed by Zacks expected $172.9 million.
For the year, the company reported a loss of $136.2 million, or $1.22 per share. Revenue was reported as $655.4 million.
NovoCure expects full-year revenue in the range of $675 million to $705 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NVCR at https://www.zacks.com/ap/NVCR